Biopharmaceutical firm Oragenics has received funding from a US
government agency for a technology which promises cost-effective
production of commercially important bioactive peptides with
unusual structures.
Sales of amino acids used in synthesis applications will reach
nearly $1 billion in 2009 and represent the fastest-growing
category in the $7 billion amino acids market.
Kyowa Hakko Kogyo has developed a new process for manufacturing
amino acid dimers - also known as di-peptides - that could increase
their use as components in infusions and enteral nutrition
products.